Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
NCT00093756
Completed
This phase I/II trial (phase I closed to accrual as of 09/29/2009) is studying the side effects and best dose of bortezomib, paclitaxel, and carboplatin when given with radiation therapy and to see how well they work in treating patients with stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2017
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +142 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
NCT01331941
Completed
This is a phase 1, open-label pharmacokinetic study where up to 40 subjects with advanced solid tumors (up to 6-10 with normal renal function and up to 18-30 with varying degrees of renal dysfunction) will receive weekly doses of AMG 386 intravenously. The primary objective is to evaluate the pharmacokinetics (PK) of single agent AMG 386 in subjects with various degrees of renal function. Once the AMG 386 PK characterization is complete in the first 5 weeks of the study, all subjects will be all... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2017
Locations: Research Site, Atlanta, Georgia +3 locations
Conditions: Advanced Solid Tumors, Kidney Disease, Renal Impairment
Register for Updates
Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.
NCT02405910
Withdrawn
Phase II study to determine progression free survival (PFS) of nab-paclitaxel administered in combination with gemcitabine, at two different dose combinations as first line therapy in patients with unresectable stage IIIB/stage IV non-squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2017
Locations: West Virginia University Hospitals - Mary Babb Randolph Cancer Center, Morgantown, West Virginia
Conditions: Non-small Cell Lung Cancer
Register for Updates
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
NCT01307891
Completed
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in American women. Metastatic disease including metastatic breast cancer unfortunately remains incurable. One reason is due to the inability to develop specific therapies for specific cancer subsets. The use of modern genomic techniques has significantly enhanced our recent understanding of breast cancer biology. Five distinct breast cancer subsets have been recognized, one of which is basal-like b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2017
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +9 locations
Conditions: Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
Register for Updates
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
NCT00470366
Completed
RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. PU... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2017
Locations: USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California +1 locations
Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Register for Updates
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00526890
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenomethionine may slow the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with selenomethionine and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well sele... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2017
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Lung Cancer
Register for Updates
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
NCT01721525
Completed
This study seeks to develop a new induction chemotherapy regimen which is a combination of two pill drugs taken by mouth and two drugs given by vein. This is a phase I study, which means that the primary goal is to establish the recommended dose of an investigational drug when added to chemotherapy. The researchers wish to evaluate the effects, good and bad, of the investigational drug.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2017
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey +1 locations
Conditions: Head and Neck Cancer, Squamous Cell Cancer
Register for Updates
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
NCT01411410
Completed
This open label Phase 1 study involves treating subjects with advanced cancer with BAY80-6946 in combination with paclitaxel. It will determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of BAY80-6946 in combination with paclitaxel. The trial will involve multiple participating sites from the US. Following determination of the MTD, an expansion cohort of 20 evaluable subjects with breast cancer was planned. Finally, 16 patients have been enrolled to treatment (Cohor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2017
Locations: Not set, Saint Louis, Missouri +2 locations
Conditions: Neoplasms
Register for Updates
Treatment With Nab-paclitaxel in Cutaneous SCC
NCT02076243
Terminated
This is an investigator initiated phase II study to assess the efficacy of a chemotherapy called nab-paclitaxel as first line cytotoxic chemotherapy in subjects with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (SCC). All subjects receive the treatment by vein weekly and receive the same dose of the treatment. The risk of developing cutaneous SCC is approximately 10% in a lifetime. The vast majority are treated surgically and do not recur. However a small percen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2017
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Cutaneous Squamous Cell Carcinoma
Register for Updates
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT01966003
Completed
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/21/2017
Locations: Research Site, Bismarck, North Dakota +3 locations
Conditions: Non-small Cell Lung Cancer Metastatic
Register for Updates
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
NCT01009515
Terminated
The number of melanoma cases has been steadily increasing over the past few decades. For many patients with metastatic melanoma, there are no effective therapies. The goal of this study is to determine whether a combination drug treatment of carboplatin, paclitaxel and temozolomide is effective in the treatment of metastatic or recurrent melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2017
Locations: Hematology Oncology Associates, Albuquerque, New Mexico +2 locations
Conditions: Melanoma
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01646762
Terminated
This phase II trial studies how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with multiple myeloma that has returned or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2017
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Refractory Plasma Cell Myeloma
Register for Updates